Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II cli… Read more
Revance Therapeutics, Inc. (RVNC) - Total Liabilities
Latest total liabilities as of September 2024: $624.59 Million USD
Based on the latest financial reports, Revance Therapeutics, Inc. (RVNC) has total liabilities worth $624.59 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Revance Therapeutics, Inc. - Total Liabilities Trend (2011–2023)
This chart illustrates how Revance Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Revance Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Revance Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ProSiebenSat.1 Media SE
PINK:PBSFF
|
USA | $4.00 Billion |
|
Trilogy Metals Inc
NYSE MKT:TMQ
|
USA | $455.00K |
|
Blend Labs Inc
NYSE:BLND
|
USA | $47.25 Million |
|
AXTRART_AXTRA FUTURE CITY
BK:AXTRART
|
Thailand | ฿3.58 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥630.58 Million |
|
Alivus Life Sciences Limited
NSE:ALIVUS
|
India | ₹6.23 Billion |
|
Amorepacific Group
KO:002795
|
Korea | ₩1.39 Trillion |
|
Betagro Public Company Limited
F:J74
|
Germany | €37.92 Billion |
Liability Composition Analysis (2011–2023)
This chart breaks down Revance Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Revance Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Revance Therapeutics, Inc. (2011–2023)
The table below shows the annual total liabilities of Revance Therapeutics, Inc. from 2011 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $630.06 Million | +10.67% |
| 2022-12-31 | $569.30 Million | +23.04% |
| 2021-12-31 | $462.69 Million | +33.75% |
| 2020-12-31 | $345.93 Million | +201.34% |
| 2019-12-31 | $114.80 Million | +42.21% |
| 2018-12-31 | $80.73 Million | +200.61% |
| 2017-12-31 | $26.85 Million | -1.59% |
| 2016-12-31 | $27.29 Million | +20.91% |
| 2015-12-31 | $22.57 Million | +40.19% |
| 2014-12-31 | $16.10 Million | -91.07% |
| 2013-12-31 | $180.19 Million | -21.71% |
| 2012-12-31 | $230.15 Million | +17.78% |
| 2011-12-31 | $195.41 Million | -- |